A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Public ClinicalTrials.gov record NCT02301117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Renal Impairment
Study identification
- NCT ID
- NCT02301117
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Interventions
- TAS-102 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2014
- Primary completion
- Jun 18, 2019
- Completion
- Jun 18, 2019
- Last update posted
- Sep 4, 2024
2015 – 2019
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Clinical Site | Phoenix | Arizona | 85054 | — |
| Duarte Clinical Site | Duarte | California | 91010 | — |
| Santa Monica Clinical Site | Santa Monica | California | 90095 | — |
| Gainesville Clinical Site | Gainesville | Florida | 32610 | — |
| Baltimore Clinical Site | Baltimore | Maryland | 21231 | — |
| Boston Clinical Site | Boston | Massachusetts | 02111 | — |
| Cleveland Clinical Site | Cleveland | Ohio | 44106 | — |
| Cleveland Clinical Site | Cleveland | Ohio | 44195 | — |
| Pittsburgh Clinical Site | Pittsburgh | Pennsylvania | 15232 | — |
| Dallas Clinical Site | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02301117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2024 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02301117 live on ClinicalTrials.gov.